Table 1.
Inhibitory immunotherapy agents included in recruiting clinical trials for head and neck cancer.
| Drug Target | Drugs | Trials* |
|---|---|---|
|
| ||
| Anti-PD-1; Anti-PD-L1 | ABBV151 (also targets TGF-β) | I-NCT03821935 |
| Abemaciclib | I/II-NCT03655444 | |
| Alisertib | I/II-NCT04555837 | |
| Atezolizumab | I-NCT03841110, I-NCT04096638, I/II-NCT03829501, I/II-NCT04471415, II-NCT03228667, II/III-NCT01810913, III-NCT03452137 | |
| Avelumab | I-NCT03498378, II-NCT02554812, II-NCT03228667 | |
| Bintrafusp Alpha / M7824 (also targets TGF-β) | I/II-NCT04220775, I/II-NCT04247282 | |
| Cemiplimab | I/II-NCT03684785, II-NCT03565783, II-NCT03916627, II-NCT04242173 | |
| GEN1046 | I/II-NCT03917381 | |
| Durvalumab | I-NCT03381183, I-NCT03618654, I-NCT03635164, I-NCT03739931, I/II-NCT03522584, I/II-NCT03618134, II-NCT02827838, II-NCT03174275, II-NCT03228667, II-NCT03529422, II-NCT03691714, I/II-NCT02643303, II/III-NCT03258554 | |
| Nivolumab | I-NCT02636036, I-NCT03565445, I-NCT03690986, I-NCT03758781, I-NCT03829436, I-NCT03841110, I-NCT03906526, I/II-NCT02955290, I/II-NCT03247712, I/II-NCT03311334, I/II-NCT03370276, I/II-NCT03435640, I/II-NCT03655444, I/II-NCT03735628, I/II-NCT04180215, I/II-NCT04349267, II-NCT03228667, II-NCT03341936, II-NCT03355560, II-NCT03521570, II-NCT03646461, II-NCT03715946, II-NCT03799445, II-NCT03829722, II-NCT03854032, II-NCT03878979, II-NCT03944915, II-NCT04080804, II-NCT04326257 | |
| PDR001 | I-NCT01351103 | |
| Pembrolizumab | I-NCT02376699, I-NCT02575404, I-NCT02783300, I-NCT03236935, I-NCT03245489, I-NCT03454451, I-NCT03565445, I-NCT03590054, I-NCT03647163, I-NCT03666273, I-NCT03799003, I-NCT03841110, I-NCT03849469, I-NCT04007744, I-NCT04187872, I-NCT04234113, I-NCT04344795, I-NCT04348916, I-NCT04429542, I-NCT04452214, I/II-NCT02799095, I/II-NCT02955290, I/II-NCT03138889, I/II-NCT03311334, I/II-NCT03474497, I/II-NCT03650764, I/II-NCT03674567, I/II-NCT03684785, I/II-NCT03684785, I/II-NCT03735290, I/II-NCT03789097, I/II-NCT04034225, I/II-NCT04060342, I/II-NCT04193293, I/II-NCT04555837, II-NCT02289209, II-NCT02641093, II-NCT02769520, II-NCT02777385, II-NCT02841748, II-NCT03049618, II-NCT03082534, II-NCT03085719, II-NCT03228667, II-NCT03383094, II-NCT03468218, II-NCT03546582, II-NCT03625323, II-NCT03645928, II-NCT03771820, II-NCT03823131, II-NCT03993353, II-NCT04144517, II-NCT04150900, II-NCT04220866, II-NCT04369937, II-NCT04414540, II-NCT04428151, III-NCT03765918, III-NCT04128696, III-NCT04199104, IV-NCT04489888 | |
| Sintilimab | III-NCT03748134 | |
| SL-279252 | I-NCT03894618 | |
| Tislelizumab | III-NCT03783442 | |
| TPST-1120 | I-NCT03829436, I-NCT04344795 | |
| XmAb20717 (also targets CTLA-4) | I-NCT03517488 | |
| XmAb23104 (also targets ICOS) | I-NCT03752398 | |
|
| ||
| Anti-CTLA-4 | Ipilimumab | I-NCT02812524, I-NCT03690986, I-NCT04290546, II-NCT03799445, II-NCT04080804, II-NCT04326257 |
| Tremelimumab | I/II-NCT02643303, I/II-NCT03522584, I/II-NCT03618134, II-NCT03693612 | |
| XmAb20717 (also targets PD-1) | I-NCT03517488 | |
| XmAb22841 (also targets LAG-3) | I-NCT03849469 | |
|
| ||
| Anti-LAG-3 | Eftilagimod alpha | II-NCT03625323 |
| INCAGN02385 | I-NCT03538028 | |
| Relatlimab | II-NCT04326257, II-NCT04080804 | |
| XmAb 22841 (also targets CTLA-4) | I-NCT03849469 | |
|
| ||
| Anti-TIM3 | INCAGN02390 | I-NCT03652077 |
|
| ||
| Anti-Galectin | GR-MD-02 | I-NCT02575404 |
|
| ||
| Anti-CD39/HLA-G | TTX-080 | I-NCT04485013 |
|
| ||
| Anti-CD94/NKG 2A | Monalizumab | I/II-NCT02643550 |
|
| ||
| Anti-ILDR2 | BAY1905254 | I-NCT03666273 |
|
| ||
| Anti-NRP1 | ASP1948 | I-NCT03565445 |
|
| ||
| Anti-KIR (NK cells) | Lirilumab | II-NCT03341936 |
|
| ||
| Anti-S15 (M2 macrophages) | NC318 | I/II-NCT03665285 |
|
| ||
| Anti-Semaphorin 4D | VX15/2503 | I-NCT03690986 |
|
| ||
| Anti-inhibitor of apoptosis proteins | Debio 1143 | III-NCT04459715 |
|
| ||
| Nitric oxide synthase inhibitor | L-NMMA | I-NCT03236935 |
|
| ||
| Anti-VEGF; Anti-PGE2 | Cabozantinib | I-NCT03667482, II-NCT03468218 |
| Lenvatinib | I-NCT03524326, II-NCT04428151, III-NCT04199104 | |
| Ramucirumab | I/II-NCT03650764 | |
| TPST-1495 | I-NCT04344795 | |
|
| ||
| Anti-IDO-1 | Epacadostat | II-NCT03823131 |
| BAY2416964 | I-NCT04069026 | |
| BMS-986205 | II-NCT03854032 | |
|
| ||
| Anti-TGF-β | ABBV151 (also targets PD-1) | I-NCT03821935 |
| BCA101 | I-NCT04429542 | |
| Bintrafusp Alpha (also targets PD-L1) | I/II-NCT04220775 | |
| PF-06940434 | I-NCT04152018 | |
|
| ||
| Colony-stimulating factor inhibitor | PD 0360324 | II-NCT02554812 |
|
| ||
| Anti-CCR4 | FLX475 | I/II-NCT03674567 |
*
Phase of study (I-IV) and National Clinical Trial (NCT) numbers as registered with www.clinicaltrials.gov. Only trials that were actively recruiting at the time of manuscript writing are included.